Product Description
The global uterine fibroid embolization (UFE) device market size is estimated to increase over the forecast period to reach $92 million by 2027.
The majority of the global uterine fibroid embolization device market share was controlled by Merit Medical Systems and Boston Scientific. This global market research spans over 70 countries and includes microsphere procedures and PVA particle procedures.
Uterine fibroid embolization (UFE), also known as uterine artery embolization, is a radiology treatment for fibroids. This procedure does not involve general anesthesia and is appropriate for women who want an alternative to a myomectomy, also known as fibroidectomy. It is a much less invasive way to treat fibroids than a hysterectomy, has a much shorter recovery time, and leaves almost no scarring.
Market Data Included
- Unit Sales, Average Selling Prices, Market Size & Growth Trends
- Procedure Numbers
- COVID-19 Impact Analysis
- Market Drivers & Limiters
- Market Forecasts Until 2027, and Historical Data to 2017
- Recent Mergers & Acquisitions
- Company Profiles and Product Portfolios
- Leading Competitors
Procedure Numbers
Throughout this study on uterine fibroid embolization device market, iData Research has performed an analysis on Microsphere and PVA Particle procedure numbers in order to increase the accuracy of our market sizing, and provide you with the volume of procedures over a 10-year range and across 70 countries.
Uterine Fibroid Embolization Device Market Insights
The uterine fibroid embolization market will experience moderate growth over the forecast period. The total market is comprised of the microsphere and PVA particle market sub-segments. When it comes to the segments, the microsphere segment accounted for the vast majority of the UFE market in 2020 because microspheres are preferred by physicians. Both the microsphere and PVA particle markets are expected to be significantly impacted by the COVID-19 pandemic. However, the impacts on this market as well as the procedures the market is in competition with are further discussed within the report.
Market Share Insights
The global pelvic organ prolapse repair device market was controlled by Merit Medical Systems and Boston Scientific.
In 2020, Merit Medical Systems was the clear leader of the total global uterine fibroid embolization device market, with the vast majority of market share. This was the first company to receive FDA approval to market the Embosphere®Microspheres as a product for uterine fibroid embolization (UFE) and thus, gave it a stronghold on the microsphere market that it has since maintained.
Research Regional Coverage
Throughout this report, iData Research has covered over 70 countries across the globe in great detail. Each global region may be purchased as a stand-alone report, tailoring the data to your needs. The regions covered are:
- North America (the United States and Canada)
- Latin America (Brazil, Mexico, Colombia, Argentina, Peru, Chile, Venezuela, and Other)
- Western Europe (Germany, France, Italy, Spain, Switzerland, Austria, Portugal, Benelux, Scandinavia, and Other)
- Central and Eastern Europe (Poland, Turkey, Russia, Greece, Czech Republic, Croatia, Bulgaria, Ukraine, Kazakhstan, Hungary, Romania, Baltic States (Estonia, Latvia, and Lithuania), and Other)
- Middle East (Saudi Arabia, UAE, Israel, Iran, Kuwait, Qatar, Bahrain, Oman, and Other)
- Asia Pacific (China, Japan, South Korea, India, Australia, Singapore, Indonesia, Malaysia, Thailand, the Philippines, Brunei, Myanmar, Cambodia, Vietnam, New Zealand, Taiwan, Hong Kong, and Other)
- Africa South Africa, Egypt, Morocco, Ghana, Nigeria, Libya, Sudan, Uganda, Kenya, and Other)
